NEW YORK (GenomeWeb) – St. Jude Children's Research Hospital has appointed James Downing as its new CEO, effective July 15. Downing most recently served as deputy director, executive vice president, and scientific director of the hospital. He will succeed William Evans, who is retiring as CEO after 10 years and returning full time to his pharmacogenomics research program at St. Jude.


EpiCypher, an epigenomics products and services firm, has named Sam Tetlow to be its first CEO and to serve on the board of directors.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.